Logo image of OTLK

OUTLOOK THERAPEUTICS INC (OTLK) Stock Price, Quote, News and Overview

NASDAQ:OTLK - Nasdaq - US69012T3059 - Common Stock - Currency: USD

1.68  -0.01 (-0.59%)

After market: 1.72 +0.04 (+2.38%)

OTLK Quote, Performance and Key Statistics

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (6/18/2025, 8:17:19 PM)

After market: 1.72 +0.04 (+2.38%)

1.68

-0.01 (-0.59%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High9.25
52 Week Low0.87
Market Cap70.88M
Shares42.19M
Float30.31M
Yearly DividendN/A
Dividend YieldN/A
PE6.72
Fwd PEN/A
Earnings (Next)08-12 2025-08-12/bmo
IPO06-13 2016-06-13


OTLK short term performance overview.The bars show the price performance of OTLK in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 15

OTLK long term performance overview.The bars show the price performance of OTLK in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of OTLK is 1.68 USD. In the past month the price decreased by -1.18%. In the past year, price decreased by -77.98%.

OUTLOOK THERAPEUTICS INC / OTLK Daily stock chart

OTLK Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.06 327.65B
AMGN AMGEN INC 13.95 155.74B
GILD GILEAD SCIENCES INC 13.95 134.34B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.15B
REGN REGENERON PHARMACEUTICALS 11.59 55.45B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 40.72B
ARGX ARGENX SE - ADR 93.55 32.85B
ONC BEONE MEDICINES LTD-ADR 6.47 27.35B
BNTX BIONTECH SE-ADR N/A 25.10B
NTRA NATERA INC N/A 23.35B
BIIB BIOGEN INC 8 18.54B
INSM INSMED INC N/A 18.12B

About OTLK

Company Profile

OTLK logo image Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 23 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Company Info

OUTLOOK THERAPEUTICS INC

111 S. Wood Avenue, Unit #100

Iselin NEW JERSEY 08852 US

CEO: Lawrence A. Kenyon

Employees: 23

OTLK Company Website

OTLK Investor Relations

Phone: 16096193990

OUTLOOK THERAPEUTICS INC / OTLK FAQ

What is the stock price of OUTLOOK THERAPEUTICS INC today?

The current stock price of OTLK is 1.68 USD. The price decreased by -0.59% in the last trading session.


What is the ticker symbol for OUTLOOK THERAPEUTICS INC stock?

The exchange symbol of OUTLOOK THERAPEUTICS INC is OTLK and it is listed on the Nasdaq exchange.


On which exchange is OTLK stock listed?

OTLK stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OUTLOOK THERAPEUTICS INC stock?

12 analysts have analysed OTLK and the average price target is 10.71 USD. This implies a price increase of 537.5% is expected in the next year compared to the current price of 1.68. Check the OUTLOOK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OUTLOOK THERAPEUTICS INC worth?

OUTLOOK THERAPEUTICS INC (OTLK) has a market capitalization of 70.88M USD. This makes OTLK a Micro Cap stock.


How many employees does OUTLOOK THERAPEUTICS INC have?

OUTLOOK THERAPEUTICS INC (OTLK) currently has 23 employees.


What are the support and resistance levels for OUTLOOK THERAPEUTICS INC (OTLK) stock?

OUTLOOK THERAPEUTICS INC (OTLK) has a support level at 1.67 and a resistance level at 1.81. Check the full technical report for a detailed analysis of OTLK support and resistance levels.


Should I buy OUTLOOK THERAPEUTICS INC (OTLK) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OUTLOOK THERAPEUTICS INC (OTLK) stock pay dividends?

OTLK does not pay a dividend.


When does OUTLOOK THERAPEUTICS INC (OTLK) report earnings?

OUTLOOK THERAPEUTICS INC (OTLK) will report earnings on 2025-08-12, before the market open.


What is the Price/Earnings (PE) ratio of OUTLOOK THERAPEUTICS INC (OTLK)?

The PE ratio for OUTLOOK THERAPEUTICS INC (OTLK) is 6.72. This is based on the reported non-GAAP earnings per share of 0.25 and the current share price of 1.68 USD. Check the full fundamental report for a full analysis of the valuation metrics for OTLK.


What is the Short Interest ratio of OUTLOOK THERAPEUTICS INC (OTLK) stock?

The outstanding short interest for OUTLOOK THERAPEUTICS INC (OTLK) is 10.62% of its float. Check the ownership tab for more information on the OTLK short interest.


OTLK Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to OTLK. When comparing the yearly performance of all stocks, OTLK is a bad performer in the overall market: 91.94% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OTLK Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to OTLK. Both the profitability and financial health of OTLK have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OTLK Financial Highlights

Over the last trailing twelve months OTLK reported a non-GAAP Earnings per Share(EPS) of 0.25. The EPS increased by 105.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA 108.58%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%74.19%
Sales Q2Q%N/A
EPS 1Y (TTM)105.05%
Revenue 1Y (TTM)N/A

OTLK Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to OTLK. The Buy consensus is the average rating of analysts ratings from 12 analysts.


Ownership
Inst Owners16.85%
Ins Owners0.18%
Short Float %10.62%
Short Ratio5.46
Analysts
Analysts83.33
Price Target10.71 (537.5%)
EPS Next Y21.77%
Revenue Next YearN/A